Literature DB >> 12136524

Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide.

A D Varvarigou1, F Scopinaro, L Leondiadis, V Corleto, O Schillaci, G De Vincentis, T G Sourlingas, K E Sekeri-Pataryas, G P Evangelatos, A Leonti, S Xanthopoulos, G Delle Fave, S C Archimandritis.   

Abstract

A new pentadecapeptide bombesin analogue was prepared by Fmoc synthesis, purified by HPLC and identified by electron ionization mass spectrometry. The biological activity of the new peptide was tested on isolated human colonic muscle cells and compared to native bombesin. Labelling of the new biomolecule with Tc-99m yielded a single radioactive species which remained stable at room temperature for eight hours. In a binding assay, the radiolabelled peptide showed high affinity for oat-cell carcinoma (Kd = 9.8 nM) and colorectal adenocarcinoma (Kd = 27.2 nM). Biodistribution studies, performed in normal rodents, indicated uptake by organs that normally express bombesin receptors, such as liver, intestines and kidneys. Scintigraphic studies, performed in nude mice transplanted with small cell lung carcinoma and colon cancer cells, showed significant tumor uptake two hours p.i. The new synthetic pentadecapeptide appears to have promise for several malignancies, including oat-cell lung carcinoma, colorectal cancer and gastroenteropancreatic (GEP) tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12136524     DOI: 10.1089/10849780260179288

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  6 in total

1.  99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes.

Authors:  Francesco Scopinaro; Giuseppe De Vincentis; Alexandra D Varvarigou; Cesare Laurenti; Francesco Iori; Silvia Remediani; Stella Chiarini; Salvatore Stella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

Review 2.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

Authors:  Susan L Deutscher; Said D Figueroa; Senthil R Kumar
Journal:  J Labelled Comp Radiopharm       Date:  2009-12-01       Impact factor: 1.921

Review 4.  Radiolabelled peptides for oncological diagnosis.

Authors:  Peter Laverman; Jane K Sosabowski; Otto C Boerman; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 5.  Targeting prostate cancer with radiolabelled bombesins.

Authors:  Theodosia Maina; Berthold Nock; Stephen Mather
Journal:  Cancer Imaging       Date:  2006-11-08       Impact factor: 3.909

6.  A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis.

Authors:  Charalampos Tsoukalas; Dimitrios Psimadas; George A Kastis; Vassilis Koutoulidis; Adrian L Harris; Maria Paravatou-Petsotas; Maria Karageorgou; Lars R Furenlid; Lia A Moulopoulos; Dimosthenis Stamopoulos; Penelope Bouziotis
Journal:  Front Chem       Date:  2018-06-20       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.